-5%
Verquv is indicated to reduce the risk of cardiovascular death and hospitalization in adults with symptomatic chronic heart failure (ejection fraction <45%) who recently required hospitalization or outpatient IV diuretics.
- Vericiguat directly stimulates soluble guanylate cyclase (sGC), a key enzyme in the nitric oxide (NO)–cGMP pathway.
- Enhances intracellular cGMP production, leading to vasodilation and improved cardiac function
- Works both independently of NO and synergistically with NO
- Improves vascular tone, cardiac contractility, and reduces cardiac remodeling
- Addresses impaired NO–sGC–cGMP signaling seen in heart failure